News
VRTX
400.76
-1.02%
-4.15
Crispr Therapeutics: Now Is The Time To Buy
CRISPR Therapeutics' stock has declined in value despite recent FDA approvals for its groundbreaking gene editing technology. The company's pipeline of treatments for various diseases presents a significant opportunity for future growth and market expansion. CRISPR has enough cash on hand to fund operations for at least 24 months.
Seeking Alpha · 7h ago
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), HealthStream (HSTM) and Vertex Pharmaceuticals (VRTX)
TipRanks · 12h ago
Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.
Two drugmakers not named Novo Nordisk have big catalysts on the horizon. Vertex Pharmaceuticals has the first CRISPR gene-editing therapy for cystic fibrosis. Viking Therapeutics has a big opportunity in the obesity market. The company's obesity drugs may be better than Novo's Wegovy.
The Motley Fool · 13h ago
Vertex Doesn't Seem To Have Engaged With Other Players Before Alpine Deal -- Market Talk
Analysts say Vertex Pharmaceuticals did not engage with other major player in the kidney-disease treatment space. Vertex's deal for Alpine Therapeutics is for a treatment for a common kidney disease. The two companies are both developing treatments for the disease.
Dow Jones · 1d ago
Edgewise gets EU orphan drug status for muscular dystrophy drug
Edgewise gets EU orphan drug status for muscular dystrophy drug. Edgewise Therapeutics has received orphan drug designation from EU regulators for its drug candidate sevasemten. The drug candidate is in the treatment of Becker muscular dy Strophy and Duchenne muscular dystrophy.
Seeking Alpha · 1d ago
Vertex Pharmaceuticals in T1D Licensing Pact With TreeFrog Therapeutics
Vertex Pharmaceuticals has struck an exclusive licensing agreement with privately held TreeFrog Therapeutics. Vertex says it will receive an exclusive license to the company's cell-manufacturing technology. The agreement is to bolster production of its cell therapies for type-1 diabetes, or T1D.
Dow Jones · 1d ago
Baron Health Care Fund Q1 2024 Shareholder Letter
Baron Health Care Fund advanced 8.92% in the quarter ended March 31, 2024. The Fund's performance was in line with the Russell 3000 Health Care Index and the S&P 500 Index. Investments in health care equipment, pharmaceuticals, and life sciences added the most value in the period.
Seeking Alpha · 1d ago
Vertex in-licenses cell therapy technology for diabetes candidates
Vertex Pharmaceuticals in-licenses cell therapy technology for diabetes candidates. French biotech TreeFrog Therapeutics to obtain exclusive license for C-Stem's cell manufacturing technology for type 1 diabetes. The company is eligible to receive up to $215M in milestone payments.
Seeking Alpha · 1d ago
Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies
NASDAQ · 1d ago
VERTEX PHARMACEUTICALS INC - VERTEX WILL FUND ALL RESEARCH AND DEVELOPMENT COSTS RELATED TO THE COLLABORATION
Reuters · 1d ago
VERTEX PHARMACEUTICALS INC - VERTEX WILL BE RESPONSIBLE FOR ALL DEVELOPMENT AND COMMERCIALIZATION OF ITS CELL THERAPIES UNDER DEAL
Reuters · 1d ago
Vertex Pharmaceuticals Just Made 2 Big Moves. Is the Stock a Buy?
Vertex Pharmaceuticals is known for treating cystic fibrosis, but the company is broadening its portfolio. The company's next big opportunity is the treatment of chronic pain. Vertex recently bought Alpine Immune Sciences for $4.9 billion in cash. The biotech's stock looks like a steal right now.
The Motley Fool · 1d ago
Arcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic Fibrosis
Arcturus Therapeutics' ARCT-032 gene therapy for cystic fibrosis has been designated as an "orphan drug" in the U.S. And Europe. The therapy has the potential to generate significant revenues, similar to Vertex Pharmaceuticals' Trikafta treatment. Arcturus has a potential to become profitable with the success of their other therapies.
Seeking Alpha · 1d ago
Vertex Pharma Obtains Exclusive License To TreeFrog's Cell Manufacturing Technology, C-Stem
NASDAQ · 1d ago
BRIEF-Vertex And Treefrog Therapeutics Announce Licensing Agreement And Collaboration To Optimize Production Of Vertex's Cell Therapies For Type 1 Diabetes
Vertex And Treefrog Therapeutics Announce Licensing Agreement And Collaboration To Optimize Production Of Vertex's Cell Therapies For Type 1 Diabetes. Vertex and Treefrog will work together to optimize production of cell therapies for type 1 diabetes. The two companies will share $540 million in total.
Reuters · 1d ago
Vertex Pharmaceuticals (VRTX) Gets a Buy from Piper Sandler
TipRanks · 2d ago
If You'd Invested $10,000 in Vertex Pharmaceuticals 5 Years Ago, Here's How Much You'd Have Today
Vertex Pharmaceuticals' shares have gained 118% over the past five years. The company has been through ups and downs. But the biotech company is expanding beyond cystic fibrosis. Vertex recently won approval for a gene-editing treatment for blood disorders. Now is a great time to hold on to your shares of Vertex.
The Motley Fool · 2d ago
Looking for Once-in-a-Generation Investment Opportunities? Here Are 3 Magnificent Stocks to Buy Right Now
These stocks could be near major inflection points. Occidental Petroleum is at the forefront of developing carbon capture technology. Vertex Pharmaceuticals commands a monopoly in treating the underlying cause of cystic fibrosis. UiPath is a leader in robotic process automation and is a once-in-a-generation investment opportunity.
The Motley Fool · 2d ago
Weekly Report: what happened at VRTX last week (0415-0419)?
Weekly Report · 2d ago
Buy Rating on Vertex Pharmaceuticals: Risinger’s Confidence in VX-548’s Billion-Dollar Potential and FDA Progress
TipRanks · 2d ago
More
Webull provides a variety of real-time VRTX stock news. You can receive the latest news about Vertex Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About VRTX
Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on investing in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has four approved medicines that treat the underlying cause of cystic fibrosis (CF), and one approved therapy that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT). Its pipeline includes clinical-stage programs in CF, SCD, TDT, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency. Its marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). It is developing non-autologous (allogeneic) fully differentiated, stem-cell derived islet cell therapies designed to replace insulin-producing islet cells that are destroyed in people with T1D.